Inconsistent results, inaccurate claims plague direct-to-consumer gene tests.

B. Kuehn

DOI: https://doi.org/10.1001/jama.2010.1328

2010-09-22

Abstract:DESPITE HAVING LIVED FOR 13 years with a pacemaker to treat atrial fibrillation, one “undercover consumer” participating in a recent Government Accountability Office (GAO) investigation was told by 4 companies providing direct-toconsumer genetic tests that he had only an average or below-average risk for developing the condition. His results and those of 4 other DNA donors who participated in the GAO investigation raise serious concerns about the clinical validity and reliability of genetic tests that are marketed directly to consumers. Additionally, when the investigation probed the companies’ marketing practices, it identified deceptive or misleading claims being used to sell the tests or other products. The results of the GAO investigation, which were requested by legislators, were presented during a July hearing of the US House of Representatives on the tests, which claim to offer consumers a genome-wide analysis of their risk of developing certain medical conditions or traits (http://energycommerce .house.gov/index.php?option=com _content&view=article&id=2083 :hearing-on-direct-to-consumer -genetic-testing-and-the-consequences -to-the-public-health&catid=133 :subcommittee-on-oversight-and -investigations&Itemid=73). The tests, which can cost $230 to $1000 and are marketed to consumers over the Internet, are receiving increased scrutiny from legislators, regulators, and clinicians. In letters sent in May, June, and July to several companies offering direct-to-consumer tests, the US Food and Drug Administration (FDA) said that the tests may require premarket approval and suggested that the agency may more aggressively regulate these products. And in fact, the FDA